Amwell® divests virtual psychiatric care business to Avel eCare in all-cash transaction
09 janv. 2025 08h00 HE
|
Amwell
Amwell divests virtual psychiatric care business to Avel eCare in all-cash transaction
Fulfilling the Promise of Noninvasive Brain Stimulation as a Precision Medicine Tool
08 janv. 2025 10h47 HE
|
Brain & Behavior Research Foundation
New York, Jan. 08, 2025 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Fulfilling the Promise of Noninvasive Brain Stimulation as a Precision...
Buckingham Psychiatry Unveils a New Way to Get Help via an Online Patient Portal
06 janv. 2025 09h50 HE
|
Buckingham Psychiatry
DOYLESTOWN, Pa., Jan. 06, 2025 (GLOBE NEWSWIRE) -- As a general psychiatrist serving the Philadelphia area, Dr. Jacob Buinewicz is always seeking ways to better engage with patients and provide...
Online Therapy Service for Teenagers Market Experiences Robust Growth, Surpassing $80 Billion in 2024, Driven by Innovative Online Therapy Models and Increased Awareness - Long-term Forecast to 2033
03 janv. 2025 06h39 HE
|
Research and Markets
Dublin, Jan. 03, 2025 (GLOBE NEWSWIRE) -- The "Online Therapy Service for Teenagers Market Report 2024" report has been added to ResearchAndMarkets.com's offering. The online therapy service market...
Magstim Horizon Inspire Transcranial Magnetic Stimulation Device Approved by UKCA for NHS & Private UK Clinics
05 déc. 2024 04h02 HE
|
Magstim EGI
UKCA Approves Magstim Horizon Inspire TMS for NHS & Private UK Clinics. UK Made System for Patient Treatment of MDD, OCD and Decreasing Anxiety.
ADHD: What You Need to Know
19 nov. 2024 10h00 HE
|
Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
Sparian Biosciences Awarded $19.5 Million Five-Year NIH/ NIDA Grant to Fund Development of SBS-226 for Opiate Use Disorder/ Opiate Withdrawal Syndrome Through Phase 1 Clinical Development
14 nov. 2024 10h06 HE
|
Sparian Biosciences, Inc
Sparian Biosciences announced that it has been awarded a $19.5 million, five-year grant to fund development of SBS-226
Sparian Biosciences Announces Formation of its Science Advisory Board
13 nov. 2024 13h01 HE
|
Sparian Biosciences, Inc
NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Sparian Biosciences, Inc. (“Sparian”), a clinical-stage CNS-focused biopharmaceutical company, is proud to announce formation of a Science Advisory Board...
Sparian Biosciences Announces Results from the Phase 1 Clinical Trial of First in Class Novel Arylepoxamide Receptor (AEAr) Agonist Analgesic SBS-1000
12 nov. 2024 10h01 HE
|
Sparian Biosciences, Inc
Sparian Biosciences announced results from the Phase 1 clinical trial of the first in class novel AEAr agonist analgesic SBS-1000.
FDA Clears Magstim Horizon INSPIRE Transcranial Magnetic Stimulation System to treat Depression, OCD, Anxious Depression
12 nov. 2024 08h11 HE
|
Magstim EGI
FDA clears Magstim INSPIRE Transcranial Magnetic Stimulation TMS system to treat patients with Depression, OCD, Anxious Depression